Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2006-003933-33-DE
EUCTR2006-003933-33-DE
Active, not recruiting
Not Applicable

Clinical value of Choline-Positron-Emission-Tomography combined with Magnetic Resonance Imaging by software fusion for pre-therapeutic staging of prostate cancer

Bundeswehr0 sitesSeptember 6, 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsClinical value of Choline-Positron-Emission-Tomography combined with Magnetic Resonance Imaging by software fusion for pre-therapeutic staging of prostate cancer referring to histopathological, postoperative results

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Clinical value of Choline-Positron-Emission-Tomography combined with Magnetic Resonance Imaging by software fusion for pre-therapeutic staging of prostate cancer referring to histopathological, postoperative results
Sponsor
Bundeswehr
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 6, 2006
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Sponsor
Bundeswehr

Eligibility Criteria

Inclusion Criteria

  • •\- preoperative suspected prostate cancer (e.g. suspect digital rectal examination and/or PSA\-Level \>10,0 ng/ml)
  • •\- radical prostatectomy as primary treatment
  • •\- no nutrition within 12 hours before PET
  • •\- no food containing choline within 24 hous before PET
  • •\- age \>50 years
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • •\- total endo\-prothesis of the hip region
  • •\- clinical or chemical detection of an acute infection
  • •\- missing patient agreement
  • •\- secondary cancer
  • •\- surgical treatment within 3 month before PET
  • •\- claustrophoby
  • •\- medical drugs with choline
  • •\- severe liver damage
  • •\- cardiac infarction
  • •\- Bradycardie (pulserate\<55/min)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Clinical relevance of Positron Emission Tomography (PET) imaging following endovascular aneurysm repair using the Nellix endoprosthesis.Abdominal aortic aneurysmenlarged artery of the abdominal aorta10002363
NL-OMON40667Rijnstate Ziekenhuis10
Completed
Phase 2
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving EnzalutamideProstate Cancer Metastatic
NCT02815033The European Uro-Oncology Group66
Completed
Not Applicable
clinical study of positron emission tomography with 3-deoxy-3-[18F]-fluoro-D-glucosehealthy adult volunteer, cancer, epilepsy, Moyamoya disease,Alzheimer&#39s disease
JPRN-UMIN000008871Center for Integrated Human Brain Science, Brain Research Institute, University of Niigata100
Completed
Not Applicable
Clinical study using positron emission tomography(PET)brain tumor,epilepsy,multiple sclerosis, neuromyelitis,Duchenne musclar dystrophy,Alzheimer&#39s disease,Down Syndrome,Hydrocephalus
JPRN-UMIN000005626Center for Integrated Human Brain Science, Brain Research Institute, University of Niigata100
Completed
Not Applicable
Evaluation of clinical utility of serum choline level as a marker of non-alcoholic steatohepatitis.on-alcoholic fatty liver diseases (Simple steatosis of the liver and non-alcoholic steatohepatitis).
JPRN-UMIN000003686Department of Pharmacology, Gifu University Graduate School of Medicine200